BIOMAT Database Logo BIOMAT Database Logo

Hepatocellular carcinoma with sarcomatous change arising after eradication of HCV via interferon therapy. 2006

Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hitachi-kinen Hospital, Yasugi-shi, Shimane 692-0011, Japan. youko-fujii@hitachi-kinen.jp

A patient was diagnosed with chronic hepatitis C at the age of 63 years. He achieved eradication of HCV via interferon (IFN). Eight years after, a hepatocellular carcinoma (HCC) was detected and treated through transarterial embolization and percutaneous ethanol injection therapy. After about 1 year, a large hypovascular tumor was detected. This tumor was surgically resected and diagnosed as an HCC with sarcomatous change. This is the first case of an HCC with sarcomatous change arising after a sustained response to IFN therapy.

UI MeSH Term Description Entries
D007372 Interferons Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. Interferon
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D019043 Vascular Neoplasms Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA. Neoplasms, Vascular,Neoplasm, Vascular,Vascular Neoplasm

Related Publications

Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change arising after radiofrequency ablation for well-differentiated hepatocellular carcinoma.
October 2003, Hepatology research : the official journal of the Japan Society of Hepatology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change arising in primary biliary cirrhosis.
February 1997, Journal of gastroenterology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change.
January 1997, Oncology reports,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change.
December 2010, La Tunisie medicale,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Incidence of hepatocellular carcinoma after HCV eradication: assessing the risk.
April 2020, Hepatobiliary surgery and nutrition,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Prognostic Significance of Sarcomatous Change in Patients with Hepatocellular Carcinoma After Surgical Resection.
December 2015, Annals of surgical oncology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization.
November 2012, Hepatology research : the official journal of the Japan Society of Hepatology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels.
January 2002, Hepato-gastroenterology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy.
January 1989, Cancer chemotherapy and pharmacology,
Youko Idobe-Fujii, and Nagako Ogi, and Keiko Hosho, and Masahiko Koda, and Yoshikazu Murawaki, and Yasushi Horie
Hepatocellular carcinoma with sarcomatous change: prompt and fatal intraabdominal recurrence after liver transplantation.
January 2009, Gastroenterologie clinique et biologique,
Copied contents to your clipboard!